Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 4/2015

01-04-2015 | Article

Plasma isoflavone concentration is associated with decreased risk of type 2 diabetes in Korean women but not men: results from the Korean Genome and Epidemiology Study

Authors: Kwang-Pil Ko, Cheong-Sik Kim, Younjhin Ahn, Seon-Joo Park, Yeon-Jeong Kim, Jae Kyung Park, Young-Khi Lim, Keun-Young Yoo, Sung Soo Kim

Published in: Diabetologia | Issue 4/2015

Login to get access

Abstract

Aims/hypothesis

To examine the association between soybean products and risk of type 2 diabetes, we measured four isoflavone biological markers—genistein, daidzein, glycitein and equol—in a nested case–control study.

Methods

The study population was composed of 693 cases (316 women and 377 men) and 698 matched controls (317 women and 381 men) within the Korean Genome and Epidemiology Study. The concentrations of isoflavone biomarkers were measured using HPLC-MS/MS on plasma samples that were collected at baseline. A stratified analysis was undertaken to examine the association between plasma isoflavone concentrations and risk of type 2 diabetes according to sex and equol production. Logistic regression models were used to compute ORs and 95% CIs adjusted for confounders.

Results

In women, compared with the lowest quartile of plasma concentration of genistein, the highest quartile exhibited a significantly decreased risk of diabetes (OR 0.58, 95% CI 0.35, 0.95). When stratified by equol-producing status in women, the OR for diabetes in the highest vs the lowest quartile of genistein concentration was 0.31 (95% CI 0.16, 0.60) in equol producers, but genistein concentration was not associated with risk of diabetes in equol non-producers (p for interaction = 0.013). In men, isoflavone concentrations were not associated with risk of diabetes, regardless of equol-producing status.

Conclusions/interpretation

High plasma concentrations of genistein were associated with a decreased risk of type 2 diabetes in women. This inverse association was prominent in equol-producing participants. These results suggest a beneficial effect of a high intake of soybean products on risk of type 2 diabetes in women.
Literature
1.
Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–1053CrossRefPubMed
2.
Meyer MR, Clegg DJ, Prossnitz ER, Barton M (2011) Obesity, insulin resistance and diabetes: sex differences and role of oestrogen receptors. Acta Physiol 203:259–269CrossRef
3.
Jayagopal V, Albertazzi P, Kilpatrick ES et al (2002) Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 25:1709–1714CrossRefPubMed
4.
Bhathena SJ, Velasquez MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76:1191–1201PubMed
5.
Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H (1999) Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res PTR 13:601–608CrossRef
6.
Mueller NT, Odegaard AO, Gross MD et al (2012) Soy intake and risk of type 2 diabetes mellitus in Chinese Singaporeans: soy intake and risk of type 2 diabetes. Eur J Nutr 51:1033–1040CrossRefPubMedCentralPubMed
7.
Morimoto Y, Steinbrecher A, Kolonel LN, Maskarinec G (2011) Soy consumption is not protective against diabetes in Hawaii: the Multiethnic Cohort. Eur J Clin Nutr 65:279–282CrossRefPubMedCentralPubMed
8.
Villegas R, Gao YT, Yang G et al (2008) Legume and soy food intake and the incidence of type 2 diabetes in the Shanghai Women's Health Study. Am J Clin Nutr 87:162–167PubMedCentralPubMed
9.
Nanri A, Mizoue T, Takahashi Y et al (2010) Soy product and isoflavone intakes are associated with a lower risk of type 2 diabetes in overweight Japanese women. J Nutr 140:580–586CrossRefPubMed
10.
Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27–32CrossRefPubMed
11.
Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577–3584PubMed
12.
Perera FP, Weinstein IB (2000) Molecular epidemiology: recent advances and future directions. Carcinogenesis 21:517–524CrossRefPubMed
13.
Liggins J, Bluck LJ, Runswick S, Atkinson C, Coward WA, Bingham SA (2000) Daidzein and genistein contents of vegetables. Br J Nutr 84:717–725PubMed
14.
Shin C, Abbott RD, Lee H, Kim J, Kimm K (2004) Prevalence and correlates of orthostatic hypotension in middle-aged men and women in Korea: the Korean Health and Genome Study. J Hum Hypertens 18:717–723CrossRefPubMed
15.
Cho N, Joo S, Kim J, Abbott RD, Kimm K, Shin C (2006) Relation of habitual snoring with components of metabolic syndrome in Korean adults. Diabetes Res Clin Pract 71:256–263CrossRefPubMed
16.
Ahn Y, Kwon E, Shim JE et al (2007) Validation and reproducibility of food frequency questionnaire for Korean genome epidemiologic study. Eur J Clin Nutr 61:1435–1441CrossRefPubMed
17.
Park MK, Song Y, Joung H, Li SJ, Paik HY (2007) Establishment of an isoflavone database for usual Korean foods and evaluation of isoflavone intake among Korean children. Asia Pac J Clin Nutr 16:129–139PubMed
18.
Grace PB, Taylor JI, Botting NP et al (2003) Quantification of isoflavones and lignans in serum using isotope dilution liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom RCM 17:1350–1357CrossRef
19.
Fujimoto K, Tanaka M, Hirao Y et al (2008) Age-stratified serum levels of isoflavones and proportion of equol producers in Japanese and Korean healthy men. Prostate Cancer Prostatic Dis 11:252–257CrossRefPubMed
20.
Hong KW, Ko KP, Ahn Y et al (2012) Epidemiological profiles between equol producers and nonproducers: a genomewide association study of the equol-producing phenotype. Genes Nutr 7:567–574CrossRefPubMedCentralPubMed
21.
Akaza H, Miyanaga N, Takashima N et al (2004) Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34:86–89CrossRefPubMed
22.
Louet JF, LeMay C, Mauvais-Jarvis F (2004) Antidiabetic actions of estrogen: insight from human and genetic mouse models. Curr Atheroscler Rep 6:180–185CrossRefPubMed
23.
Hwang JT, Park IJ, Shin JI et al (2005) Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 338:694–699CrossRefPubMed
24.
Kim HK, Nelson-Dooley C, Della-Fera MA et al (2006) Genistein decreases food intake, body weight, and fat pad weight and causes adipose tissue apoptosis in ovariectomized female mice. J Nutr 136:409–414PubMed
25.
Park HJ, Della-Fera MA, Hausman DB, Rayalam S, Ambati S, Baile CA (2009) Genistein inhibits differentiation of primary human adipocytes. J Nutr Biochem 20:140–148CrossRefPubMed
26.
Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA (2002) Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 132:3168–3171PubMed
27.
Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335–339CrossRefPubMed
28.
Shor D, Sathyapalan T, Atkin SL, Thatcher NJ (2012) Does equol production determine soy endocrine effects? Eur J Nutr 51:389–398CrossRefPubMed
29.
Andersson B, Marin P, Lissner L, Vermeulen A, Bjorntorp P (1994) Testosterone concentrations in women and men with NIDDM. Diabetes Care 17:405–411CrossRefPubMed
30.
Oh JY, Barrett-Connor E, Wedick NM, Wingard DL (2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 25:55–60CrossRefPubMed
31.
Cornwell T, Cohick W, Raskin I (2004) Dietary phytoestrogens and health. Phytochemistry 65:995–1016CrossRefPubMed
32.
Ford ES, Liu S (2005) Invited commentary: acne in adolescence—protecting the heart but damaging the prostate later in life? Am J Epidemiol 161:1102–1106CrossRefPubMed
33.
Kuiper GG, Carlsson B, Grandien K et al (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138:863–870PubMed
34.
Shelnutt SR, Cimino CO, Wiggins PA, Ronis MJ, Badger TM (2002) Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 76:588–594PubMed
35.
Sathyamoorthy N, Wang TT (1997) Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells. Eur J Cancer 33:2384–2389CrossRefPubMed
36.
Fuhrman BJ, Teter BE, Barba M et al (2008) Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women. Cancer Epidemiol Biomark Prev 17:33–42CrossRef
37.
Wu J, Oka J, Ezaki J et al (2007) Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause 14:866–874CrossRefPubMed
38.
Yuan JP, Wang JH, Liu X (2007) Metabolism of dietary soy isoflavones to equol by human intestinal microflora—implications for health. Mol Nutr Food Res 51:765–781CrossRefPubMed
39.
Ko KW, Yang SW, Cho NH (1994) The incidence of IDDM in Seoul from 1985 to 1988. Diabetes Care 17:1473–1475CrossRefPubMed
40.
Matsuura N, Ko KW, Park YS, Elliott R (1996) Molecular epidemiology of IDDM in the Western Pacific Rim Region. WHO DiaMond Molecular Epidemiology Sub-Project Group. Diabetes Res Clin Pract 34(Suppl):S117–S123CrossRefPubMed
41.
Greenland S (1977) Response and follow-up bias in cohort studies. Am J Epidemiol 106:184–187PubMed
Metadata
Title
Plasma isoflavone concentration is associated with decreased risk of type 2 diabetes in Korean women but not men: results from the Korean Genome and Epidemiology Study
Authors
Kwang-Pil Ko
Cheong-Sik Kim
Younjhin Ahn
Seon-Joo Park
Yeon-Jeong Kim
Jae Kyung Park
Young-Khi Lim
Keun-Young Yoo
Sung Soo Kim
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3463-x

Other articles of this Issue 4/2015

Diabetologia 4/2015 Go to the issue

Article

Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma

Article

Sleep restriction increases free fatty acids in healthy men

Commentary

Are we waking up to the effects of NEFA?

Article

Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance

Article

Inhibitor of differentiation proteins protect against oxidative stress by regulating the antioxidant–mitochondrial response in mouse beta cells

List of Referees

Referees 2014
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits